Physician profile
Lee M Royall
NPI 1578569067
$5,556.05
in general payments reported to CMS, 2019-2025
34 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $635 · 2021: $58.39 · 2022: $374 · 2023: $811 · 2024: $1,144 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,684 · Education: $14.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,684.12 |
| Education | $14.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,773.24 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $991.62 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $303.43 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $282.71 | 2019-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $219.29 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $211.52 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $191.68 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $182.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $168.01 | 2019-2025 | General - Hemostasis |
| Sandoz INC. | $141.03 | 2023-2025 | Hyrimoz |
| Lilly USA, LLC | $114.50 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $110.26 | 2019 | |
| Intercept Pharmaceuticals, INC. | $88.43 | 2019-2025 | |
| Pfizer INC. | $81.83 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $75.50 | 2025 | Iqirvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $75.33 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $74.08 | 2020-2024 | Linzess |
| Gilead Sciences, INC. | $49.52 | 2020-2024 | |
| Celltrion USA INC. | $44.23 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $37.70 | 2024-2025 | Suflave, Sutab |
| Qol Medical, LLC | $36.49 | 2024 | Sucraid |
| Celgene Corporation | $34.98 | 2023-2024 | Zeposia |
| Exact Sciences Corporation | $31.67 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $31.59 | 2023 | Dificid |
| Evoke Pharma, INC. | $27.37 | 2023-2024 | Gimoti |
| Novo Nordisk INC | $24.86 | 2025 | Wegovy |
| Mirum Pharmaceuticals, INC. | $23.20 | 2025 | Livmarli |
| Mallinckrodt Hospital Products INC. | $21.96 | 2023 | Terlivaz |
| Organon LLC | $21.86 | 2024 | |
| Redhill Biopharma INC. | $21.85 | 2021 | |
| Shire North American Group INC | $19.73 | 2019 | |
| Genzyme Corporation | $18.61 | 2023 | |
| Shionogi INC | $12.70 | 2020 | |
| Endo Pharmaceuticals INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Royall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.